By proceeding, you agree to our Terms of Use and Privacy Policy.
BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry.
25-27 April 2023
In 2023, there will be significant interest in glial cell models, neuroinflammatory biomarkers, and optimizing approaches to target LRKK2, TREM2, and other neurological indications. As a result, large biopharmaceutical companies are expanding their d
Event Ended
USA
Paid
Boston